DFFN
Closed
Diffusion Pharmaceuticals Inc
9.25
+0.58 (+6.69%)
Last Update: 18 Oct 2023 16:30:00
Yesterday: 8.67
Day's Range: 8.9901 - 9.26
Send
sign up or login to leave a comment!
When Written:
4.15
Diffusion Pharmaceuticals Inc is a clinical-stage biotechnology company that focuses on developing treatments for life-threatening medical conditions caused by oxygen deprivation. The company's lead product candidate, trans sodium crocetinate (TSC), is designed to enhance the diffusion of oxygen to tissues with low oxygen levels, such as those found in cancerous tumors and stroke-affected brain tissue.
Diffusion Pharmaceuticals was founded in 2001 and is headquartered in Charlottesville, Virginia. The company has partnerships with leading research institutions, including the University of Virginia and the National Cancer Institute, and has received funding from the National Institutes of Health and the Department of Defense.
In addition to its work on TSC, Diffusion Pharmaceuticals is exploring other potential applications for its technology, including the treatment of traumatic brain injury and sickle cell disease. The company is committed to advancing its innovative therapies through rigorous clinical trials and regulatory approval processes.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Diffusion Pharmaceuticals was founded in 2001 and is headquartered in Charlottesville, Virginia. The company has partnerships with leading research institutions, including the University of Virginia and the National Cancer Institute, and has received funding from the National Institutes of Health and the Department of Defense.
In addition to its work on TSC, Diffusion Pharmaceuticals is exploring other potential applications for its technology, including the treatment of traumatic brain injury and sickle cell disease. The company is committed to advancing its innovative therapies through rigorous clinical trials and regulatory approval processes.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








